Research Paper Volume 11, Issue 14 pp 4890—4899
GCN-5/PGC-1α signaling is activated and associated with metabolism in cyclin E1-driven ovarian cancer
Figure 4. Combination therapy of targeting GCN5 and CDK2 inhibits CCNE1-amplified HGSOC. Shown are inhibitory effects of shGCN5 and CDK2 inhibitor Dinaciclib in proliferation assay in (A) OVCAR-3 and (B) A2780 cells; combination therapy in cell cycle assay in (C) OVCAR-3 and (D) A2780 cells; combination therapy in apoptosis assay in (E) OVCAR-3 and (F) A2780 cells; combination therapy in Transwell (G) migration assay and (H) invasion assay, and in (I) colony formation assay; (J, K) Xenograft mouse model showing tumor inhibitory effects using genetic silencing of GCN5 and CDK2 inhibitor. (*P < 0.05; **P < 0.01)